Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 3
1977 1
1978 1
1979 4
1980 1
1982 1
1983 1
1984 1
1985 1
1986 1
1987 2
1989 1
1990 2
1991 1
1992 1
1994 2
1996 5
1997 4
1998 4
1999 4
2000 1
2001 4
2002 6
2003 3
2004 5
2005 8
2006 6
2007 10
2008 4
2009 12
2010 8
2011 13
2012 3
2013 8
2014 13
2015 8
2016 4
2017 8
2018 11
2019 16
2020 19
2021 16
2022 14
2023 14
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Results by year

Filters applied: . Clear all
Page 1
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, Ito T, Kambarov Y, Llorca PM, Oliveira-Maia AJ, Messer T, Mulhern-Haughey S, Rive B, von Holt C, Young AH, Godinov Y; ESCAPE-TRD Investigators. Reif A, et al. N Engl J Med. 2023 Oct 5;389(14):1298-1309. doi: 10.1056/NEJMoa2304145. N Engl J Med. 2023. PMID: 37792613 Clinical Trial.
More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 patients [27.1%] vs. 60 of 340 patients [17.6%]; P = 0.003) and had no relapse through week 32 after remission at week 8 (73 of 336 patients [21.7%] vs. 48 of 340 patients …
More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 patients [27.1%] vs. 60 of 340 patient …
T cells specific for α-myosin drive immunotherapy-related myocarditis.
Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, Ferrell PB, Phillips EJ, Mallal S, Johnson DB, Allison JP, Moslehi JJ, Balko JM. Axelrod ML, et al. Nature. 2022 Nov;611(7937):818-826. doi: 10.1038/s41586-022-05432-3. Epub 2022 Nov 16. Nature. 2022. PMID: 36385524 Free PMC article.
Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population.
Bergström G, Persson M, Adiels M, Björnson E, Bonander C, Ahlström H, Alfredsson J, Angerås O, Berglund G, Blomberg A, Brandberg J, Börjesson M, Cederlund K, de Faire U, Duvernoy O, Ekblom Ö, Engström G, Engvall JE, Fagman E, Eriksson M, Erlinge D, Fagerberg B, Flinck A, Gonçalves I, Hagström E, Hjelmgren O, Lind L, Lindberg E, Lindqvist P, Ljungberg J, Magnusson M, Mannila M, Markstad H, Mohammad MA, Nystrom FH, Ostenfeld E, Persson A, Rosengren A, Sandström A, Själander A, Sköld MC, Sundström J, Swahn E, Söderberg S, Torén K, Östgren CJ, Jernberg T. Bergström G, et al. Circulation. 2021 Sep 21;144(12):916-929. doi: 10.1161/CIRCULATIONAHA.121.055340. Epub 2021 Sep 20. Circulation. 2021. PMID: 34543072 Free PMC article.
Testing bronchodilator responsiveness.
Janson C, Malinovschi A, Amaral AFS, Accordini S, Bousquet J, Buist AS, Garcia-Aymerich J, Gnatiuc L, Tan W, Torén K, Zuberbier T, Burney P; all the authors. Janson C, et al. Eur Respir J. 2019 Dec 4;54(6):1902104. doi: 10.1183/13993003.02104-2019. Print 2019 Dec. Eur Respir J. 2019. PMID: 31801819 Free article. No abstract available.
Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants.
Ben-Sheetrit J, Hermon Y, Birkenfeld S, Gutman Y, Csoka AB, Toren P. Ben-Sheetrit J, et al. Ann Gen Psychiatry. 2023 Apr 21;22(1):15. doi: 10.1186/s12991-023-00447-0. Ann Gen Psychiatry. 2023. PMID: 37085865 Free PMC article.
RESULTS: SAs were associated with an increased risk for ED (cOR = 3.6, p < 0.000001, 95% CI 2.8-4.8), which remained significant after adjusting for age, SES, BMI, depression and anxiety (aOR = 3.2, p < 0.000001, 95% CI 2.3-4.4). ...

RESULTS: SAs were associated with an increased risk for ED (cOR = 3.6, p < 0.000001, 95% CI 2.8-4.8), which remained significant a

…
Pulmonary function and atherosclerosis in the general population: causal associations and clinical implications.
Engström G, Lampa E, Dekkers K, Lin YT, Ahlm K, Ahlström H, Alfredsson J, Bergström G, Blomberg A, Brandberg J, Caidahl K, Cederlund K, Duvernoy O, Engvall JE, Eriksson MJ, Fall T, Gigante B, Gummesson A, Hagström E, Hamrefors V, Hedner J, Janzon M, Jernberg T, Johnson L, Lind L, Lindberg E, Mannila M, Nilsson U, Persson A, Persson HL, Persson M, Ramnemark A, Rosengren A, Schmidt C, Skoglund Larsson L, Sköld CM, Swahn E, Söderberg S, Torén K, Waldenström A, Wollmer P, Zaigham S, Östgren CJ, Sundström J. Engström G, et al. Eur J Epidemiol. 2024 Jan;39(1):35-49. doi: 10.1007/s10654-023-01088-z. Epub 2024 Jan 2. Eur J Epidemiol. 2024. PMID: 38165527 Free PMC article.
Medical cannabis for treatment-resistant combat PTSD.
Nacasch N, Avni C, Toren P. Nacasch N, et al. Front Psychiatry. 2023 Jan 19;13:1014630. doi: 10.3389/fpsyt.2022.1014630. eCollection 2022. Front Psychiatry. 2023. PMID: 36741572 Free PMC article.

Our findings show that total sleep score, subjective sleep quality, and sleep duration significantly improved (p < 0.01). Total PTSD symptom score and its subdomains (intrusiveness, avoidance, and alertness) showed improvement (p < 0.05). However, there was no

…

Our findings show that total sleep score, subjective sleep quality, and sleep duration significantly improved (p < 0.01). Total PT

…
High prevalence of interstitial lung abnormalities in middle-aged never-smokers.
Pesonen I, Johansson F, Johnsson Å, Blomberg A, Boijsen M, Brandberg J, Cederlund K, Egesten A, Emilsson ÖI, Engvall JE, Frølich A, Hagström E, Lindberg E, Malinovschi A, Stenfors N, Swahn E, Tanash H, Themudo R, Torén K, Vanfleteren LEGW, Wollmer P, Zaigham S, Östgren CJ, Sköld CM. Pesonen I, et al. ERJ Open Res. 2023 Sep 25;9(5):00035-2023. doi: 10.1183/23120541.00035-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37753274 Free PMC article.
Chromosomal Microarray Evaluation of Fetal Ventriculomegaly.
Toren A, Alpern S, Berkenstadt M, Bar-Yosef O, Pras E, Katorza E. Toren A, et al. Isr Med Assoc J. 2020 Oct;22(10):639-644. Isr Med Assoc J. 2020. PMID: 33070489 Free article.
RESULTS: Karyotype aberrations were more common among fetuses with ventriculomegaly (6.6%) compared to controls (0%, P < 0.001). CMA aberrations were more common in the non-isolated ventriculomegaly cases (24.1%) compared to controls (6.2%, P = 0.031). ...

RESULTS: Karyotype aberrations were more common among fetuses with ventriculomegaly (6.6%) compared to controls (0%, P < 0.001). C

…
Consequences of Using Post- or Prebronchodilator Reference Values in Interpreting Spirometry.
Malinovschi A, Zhou X, Andersson A, Backman H, Bake B, Blomberg A, Caidahl K, Eriksson MJ, Eriksson Ström J, Hamrefors V, Hjelmgren O, Janson C, Karimi R, Kylhammar D, Lindberg A, Lindberg E, Liv P, Olin AC, Shalabi A, Sköld CM, Sundström J, Tanash H, Torén K, Wollmer P, Zaigham S, Östgren CJ, Engvall JE. Malinovschi A, et al. Am J Respir Crit Care Med. 2023 Aug 15;208(4):461-471. doi: 10.1164/rccm.202212-2341OC. Am J Respir Crit Care Med. 2023. PMID: 37339507

An additional 5.1% were identified as having an abnormal postbronchodilator FEV(1)/FVC ratio, and this group had more respiratory symptoms, emphysema (13.5% vs. 4.1%; P < 0.001), and self-reported physician-diagnosed chronic obstructive pulmonary disease (2.8% vs. 0.5%,

…
An additional 5.1% were identified as having an abnormal postbronchodilator FEV(1)/FVC ratio, and this group had more respiratory symptoms, …
237 results